Showing results (91-100 of 715) with videos related to
Sort By:
Pageof 72
Cancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.Current Oncology Reports|July 20, 2010
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?Meetu Agrawal, Ravin J Garg, Hagop Kantarjian, et al.Nature Reviews. Drug Discovery|February 2, 2011
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, et al.Expert Opinion on Pharmacotherapy|July 24, 2013
Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemiaAziz Nazha, Hagop Kantarjian, Jorge Cortes, et al.Expert Opinion on Investigational Drugs|June 14, 2008
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemiasElias Jabbour, Samih El Ahdab, Jorge Cortes, et al.Blood|May 6, 2009
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaAlfonso Quintás-Cardama, Xin Han, Hagop Kantarjian, et al.Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureA Megan Cornelison, Hagop Kantarjian, Jorge Cortes, et al.Current Hematologic Malignancy Reports|April 29, 2010
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemiaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.Hematology/Oncology Clinics of North America|November 8, 2011
Chronic myeloid leukemia: mechanisms of resistance and treatmentElias Jabbour, Sameer A Parikh, Hagop Kantarjian, et al.JAMA Oncology|July 17, 2015
Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary ReviewTapan M Kadia, Farhad Ravandi, Jorge Cortes, et al.Pageof 72